Outcomes | Total N = 106 | Arm 1: AZT/ABC + 3TC + LPV/r (twice daily) N = 54 | Arm 2: ABC + 3TC + EFV (once daily) N = 52 | p value |
---|---|---|---|---|
SAE | ||||
Hospitalisations and clinical SAE | 6 (5.7) | 2d (3.7) | 4e (7.7) | 0.43 |
Grade 3 or 4 adverse eventsa | 1 (0.9) | 0 (0.0) | 1 (1.9) | 0.90 |
Toxicity causing ART modificationb | 3 (2.8) | 1 (1.9) | 2 (3.8) | 0.61 |
Sleeping disorders declared by caregivers | 9 (8.5) | 4 (7.4) | 5 (9.6) | 0.74 |
Specific biological adverse eventsc | ||||
Anaemia, grade 3 and 4 | 3 (2.8) | 1 (1.9) | 2 (3.8) | 0.61 |
Neutropenia, grade 3 and 4 | 10 (9.4) | 9 (16.7) | 1 (1.9) | 0.02 |
Thrombopenia, grade 3 and 4 | 1 (0.9) | 1 (1.9) | 0 (0.0) | 1.00 |
Hyperglycaemia, grade 3 and 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
Hypercholesterolemia, grade 3 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
Hypertriglyceridemia, grade 3 and 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
Hypercreatininaemia, grade 3 and 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |
Hypertransaminasaemia AST or ALT, grade 3 and 4 | 2 (1.9) | 1 (1.9) | 1 (1.9) | 1.00 |
Hyperbilirubinaemia, grade 3 and 4 | 5 (4.7) | 3 (5.6) | 2 (3.9) | 1.00 |
Hyperamylasaemia, grade 3 and 4 | 2 (1.9) | 0 (0.0) | 2 (3.9) | 0.24 |
Hyperlipasaemia, grade 3 and 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) | - |